Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Pulmatrix and Cullgen Announce Proposed Merger
Details : The combined company will focus on targeted protein degradation technology with three programs, including CG001419, a potential first-in-class, highly active small molecule.
Brand Name : CG001419
Molecule Type : Small molecule
Upfront Cash : Undisclosed
November 13, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery
Sponsor : Astellas Pharma
Deal Size : $120.0 million
Deal Type : Collaboration
Details : Under the terms of the agreement, Astellas and Cullgen aim to develop multiple targeted protein degraders by combining Cullgen's proprietary uSMITE™ targeted protein degradation platform featuring novel E3 ligands with Astellas' drug discovery capabili...
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : $35.0 million
June 14, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery
Sponsor : Astellas Pharma
Deal Size : $120.0 million
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : AZ-CICC
Deal Size : $40.0 million
Deal Type : Financing
Cullgen Raises $40 Million in New Financing Led by AstraZeneca-CICC Fund
Details : The financing will be used to accelerate development of Cullgen's promising pipeline of targeted protein degraders featuring novel E3 ligands to potentially introduce new treatment approaches for patients battling cancer using uSMITE, Cullgen’s Protein...
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
May 08, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : AZ-CICC
Deal Size : $40.0 million
Deal Type : Financing
Lead Product(s) : CG001419
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : CG001419 is a first-in-class, selective, potent oral targeted protein degrader for treatment of neurotrophic tyrosine receptor kinase fusion-positive cancers, which have been identified in numerous solid tumors including non-small cell lung, breast, and ...
Brand Name : CG001419
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 09, 2022
Lead Product(s) : CG001419
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : CG001419
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : 3E Bioventures
Deal Size : $50.0 million
Deal Type : Series B Financing
Details : The financing will support the development of Cullgen’s technology platform and internal pipeline of targeted protein degraders in oncology and other diseases. Cullgen plan to file an IND later this year for our most advanced program, CG001419.
Brand Name : CG001419
Molecule Type : Small molecule
Upfront Cash : Undisclosed
February 25, 2021
Lead Product(s) : CG001419
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : 3E Bioventures
Deal Size : $50.0 million
Deal Type : Series B Financing
Details : The first-in-class degraders developed by Cullgen efficiently degrade mutated, disease causing forms of the BRAF protein and subsequently inhibit cancer cell growth.
Brand Name : Undisclosed
Molecule Type : Undisclosed
Upfront Cash : Not Applicable
April 07, 2020
LOOKING FOR A SUPPLIER?